Patents by Inventor Daniela Krummenacher
Daniela Krummenacher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230348398Abstract: The invention relates to a compound of formula (I) wherein R1-R4 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: April 14, 2021Publication date: November 2, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Guido GALLEY, Katrin GROEBKE ZBINDEN, Daniel HUNZIKER, Wolfgang GUBA, Stefan BERCHTOLD, Danny KRUMM, Daniela KRUMMENACHER, Manuel HILBERT
-
Publication number: 20230331682Abstract: The invention relates to a compound of formula (I) Wherein A, L, R1, R2, R3 and R4 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: June 16, 2023Publication date: October 19, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Daniela Krummenacher, Piergiorgio Francesco Tommaso Pettazzoni, Fabienne Ricklin, Claus Riemer, Juergen Wichmann
-
Publication number: 20230227411Abstract: The invention relates to a compound of formula (I) wherein R1-R3 are as defined in the description and in the claims The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: April 14, 2021Publication date: July 20, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Guido GALLEY, Katrin GROEBKE ZBINDEN, Daniel HUNZIKER, Wolfgang GUBA, Danny KRUMM, Daniela KRUMMENACHER, Manuel HILBERT
-
Publication number: 20230192623Abstract: The invention relates to a compound of formula (I) wherein R1-R3 are as defined in the description and in the claims The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: April 14, 2021Publication date: June 22, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Stefan BERCHTOLD, Guido GALLEY, Katrin GROEBKE ZBINDEN, Wolfgang GUBA, Daniel HUNZIKER, Daniela KRUMMENACHER
-
Publication number: 20220298119Abstract: The invention provides a novel compound having the general formula (I) or a pharmaceutically acceptable salt thereof. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: June 8, 2022Publication date: September 22, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, David Stephen HEWINGS, Daniel HUNZIKER, Daniela KRUMMENACHER, Piergiorgio Francesco Tommaso PETTAZZONI, Juergen WICHMANN
-
Publication number: 20220298145Abstract: The invention provides a novel compound having the general formula (I) wherein R1-R3 and X are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: June 8, 2022Publication date: September 22, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, David Stephen HEWINGS, Daniel HUNZIKER, Daniela KRUMMENACHER, Piergiorgio Francesco Tommaso PETTAZZONI, Juergen WICHMANN
-
Patent number: 11319314Abstract: The present invention relates to a compound of formula I, HetAr is a five or six membered heteroaryl group, selected from wherein R1 is hydrogen, halogen, lower alkyl, lower alkoxy or lower alkyl substituted by halogen, and may be the same or different, if two R1 occur; R2 is lower alkyl or a mono- or polydeutered derivative thereof, lower alkyl substituted by halogen or lower alkoxy, lower alkenyl unsubstituted or substituted by halogen, cycloalkyl or CH2-cycloalkyl unsubstituted or substituted by halogen, heterocycloalkyl or CH2-heterocycloalkyl unsubstituted or substituted by lower alkyl; R3 is halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen or S(O)2-lower alkyl; n is 1, 2 or 3; if n is >1, then R3 may be the same or different; or to a pharmaceutically active acid addition salt thereof, to a racemic mixture or to its corresponding enantiomer and/or an optical isomer and/or stereoisomer thereof.Type: GrantFiled: November 6, 2017Date of Patent: May 3, 2022Assignee: Hoffmann-La Roche Inc.Inventors: Bjoern Bartels, Stefan Berchtold, Guido Galley, Annick Goergler, Roland Jakob-Roetne, Daniela Krummenacher, Anja Limberg, Werner Neidhart, Hasane Ratni, Michael Reutlinger, Rosa Maria Rodriguez Sarmiento, Christian Schnider
-
Publication number: 20210309653Abstract: The present invention relates to a compound of formula I, HetAr is a five or six membered heteroaryl group, selected from wherein R1 is hydrogen, halogen, lower alkyl, lower alkoxy or lower alkyl substituted by halogen, and may be the same or different, i-f two R1 occur; R2 is lower alkyl or a mono- or polydeutered derivative thereof, lower alkyl substituted by halogen or lower alkoxy, lower alkenyl unsubstituted or substituted by halogen, cycloalkyl or CH2-cycloalkyl unsubstituted or substituted by halogen, heterocycloalkyl or CH2-heterocycloalkyl unsubstituted or substituted by lower alkyl; R3 is halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen or S(0)2-lower alkyl; n is 1, 2 or 3; if n is >1, then R3 may be the same or different; or to a pharmaceutically active acid addition salt thereof, to a racemic mixture or to its corresponding enantiomer and/or an optical isomer and/or stereoisomer thereof.Type: ApplicationFiled: November 6, 2017Publication date: October 7, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Bjoern BARTELS, Stefan BERCHTOLD, Guido GALLEY, Annick GOERGLER, Roland JAKOB-ROETNE, Daniela KRUMMENACHER, Anja LIMBERG, Werner NEIDHART, Hasane RATNI, Michael REUTLINGER, Rosa Maria RODRIGUEZ SARMIENTO, Christian SCHNIDER
-
Publication number: 20070032542Abstract: The present invention relates to a process for the preparation of enantiopure intermediates useful in the synthesis of valuable pharmaceutically active compounds, e.g. MAOB inhibitors, and to novel intermediates of formulae I and II wherein R21, R22, R23 and R24 are as defined in the description and claims.Type: ApplicationFiled: October 10, 2006Publication date: February 8, 2007Inventors: Hans Iding, Daniela Krummenacher, Beat Wirz, Woflgang Wostl
-
Patent number: 7151111Abstract: The invention relates to racemic or enantiomerically pure 4-pyrrolidino derivatives, processes for their preparation, pharmaceutical compositions comprising said derivatives, and their use in the prevention and treatment of a disease which is mediated by a monoamine oxidase B inhibitor, in particular Alzheimer's disease and senile dementia.Type: GrantFiled: September 18, 2003Date of Patent: December 19, 2006Assignee: Hoffmann-La Roche Inc.Inventors: Hans Iding, Synese Jolidon, Daniela Krummenacher, Rosa Maria Rodriguez-Sarmiento, Andrew William Thomas, Beat Wirz, Wolfgang Wostl, Rene Wyler
-
Patent number: 7148362Abstract: The present invention relates to a process for the preparation of enantiopure intermediates useful in the synthesis of valuable pharmaceutically active compounds, e.g. MAOB inhibitors, and to novel intermediates of formulae I and II wherein R21, R22, R23 and R24 are as defined in the description and claims.Type: GrantFiled: September 14, 2004Date of Patent: December 12, 2006Assignee: Hoffmann-La Roche Inc.Inventors: Hans Iding, Daniela Krummenacher, Beat Wirz, Wolfgang Wostl
-
Patent number: 7122562Abstract: The invention relates to racemic or enantiomerically pure 4-pyrrolidino derivatives, processes for their preparation, pharmaceutical compositions comprising said derivatives, and their use in the prevention and treatment of illness, in particular which is mediated by monoamine oxidase B inhibitors, in particular Alzheimer's disease or senile dementia.Type: GrantFiled: January 5, 2006Date of Patent: October 17, 2006Assignee: Hoffmann-La Roche Inc.Inventors: Hans Iding, Synese Jolidon, Daniela Krummenacher, Rosa Maria Rodriguez-Sarmiento, Andrew William Thomas, Beat Wirz, Wolfgang Wostl, Rene Wyler
-
Publication number: 20060122235Abstract: The invention relates to racemic or enantiomerically pure 4-pyrrolidino derivatives, processes for their preparation, pharmaceutical compositions comprising said derivatives, and their use in the prevention and treatment of illness, in particular which is mediated by monoamine oxidase B inhibitors, in particular Alzheimer's disease or senile dementia.Type: ApplicationFiled: January 5, 2006Publication date: June 8, 2006Inventors: Hans Iding, Synese Jolidon, Daniela Krummenacher, Rosa Rodriguez-Sarmiento, Andrew Thomas, Beat Wirz, Wolfgang Wostl, Rene Wyler
-
Patent number: 7037935Abstract: The invention relates to racemic or enantiomerically pure 4-pyrrolidino derivatives, processes for their preparation, pharmaceutical compositions comprising said derivatives, and their use in the prevention and treatment of illness, in particular which is mediated by monoamine oxidase B inhibitors, in particular Alzheimer's disease or senile dementia.Type: GrantFiled: September 18, 2003Date of Patent: May 2, 2006Assignee: Hoffmann-La Roche Inc.Inventors: Hans Iding, Synese Jolidon, Daniela Krummenacher, Rosa Maria Rodriguez-Sarmiento, Andrew William Thomas, Beat Wirz, Wolfgang Wostl, Rene Wyler
-
Publication number: 20050065204Abstract: The present invention relates to a process for the preparation of enantiopure intermediates useful in the synthesis of valuable pharmaceutically active compounds, e.g. MAOB inhibitors, and to novel intermediates of formulae I and II wherein R21, R22, R23 and R24 are as defined in the description and claims.Type: ApplicationFiled: September 14, 2004Publication date: March 24, 2005Inventors: Hans Iding, Daniela Krummenacher, Beat Wirz, Wolfgang Wostl
-
Publication number: 20040116707Abstract: The invention relates to racemic or enantiomerically pure 4-pyrrolidino derivatives, processes for their preparation, pharmaceutical compositions comprising said derivatives, and their use in the prevention and treatment of a disease which is mediated by a monoamine oxidase B inhibitor, in particular Alzheimer's disease and senile dementia.Type: ApplicationFiled: September 18, 2003Publication date: June 17, 2004Inventors: Hans Iding, Synese Jolidon, Daniela Krummenacher, Rosa Maria Rodriguez-Sarmiento, Andrew William Thomas, Beat Wirz, Wolfgang Wostl, Rene Wyler
-
Publication number: 20040106650Abstract: The invention relates to racemic or enantiomerically pure 4-pyrrolidino derivatives, processes for their preparation, pharmaceutical compositions comprising said derivatives, and their use in the prevention and treatment of illness, in particular which is mediated by monoamine oxidase B inhibitors, in particular Alzheimer's disease or senile dementia.Type: ApplicationFiled: September 18, 2003Publication date: June 3, 2004Inventors: Hans Iding, Synese Jolidon, Daniela Krummenacher, Rosa Maria Rodriguez-Sarmiento, Andrew William Thomas, Beat Wirz, Wolfgang Wostl, Rene Wyler